Acceleron preps filings for blood disorder drug luspatercept by Phil Taylor Tuesday, July 10, 2018 Acceleron and Celgene have the second phase 3 trial they wanted for beta thalassemia drug luspatercept, setting up filings in the U.S. and Europe.
